

Robert K Hills

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7260186/robert-k-hills-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

175
papers

13,367
citations

53
h-index

115
g-index

180
ext. papers

15,294
ext. citations

5
avg, IF

5.97
L-index

#	Paper	IF	Citations
175	Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. <i>Blood</i> , 2010 , 116, 354-65	2.2	1353
174	Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. <i>Lancet, The</i> , 2007 , 370, 2020-9	40	1012
173	The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. <i>Blood</i> , 2008 , 111, 2776-84	2.2	555
172	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018 , 131, 1275-1291	2.2	528
171	Assessment of Minimal Residual Disease in Standard-Risk AML. <i>New England Journal of Medicine</i> , 2016 , 374, 422-33	59.2	500
170	Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 369-77	2.2	485
169	A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. <i>Cancer</i> , 2007 , 109, 1114-24	6.4	478
168	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncology, The</i> , 2014 , 15, 986-96	21.7	410
167	Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5195-201	2.2	337
166	Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1295-303	21.7	316
165	Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3924-31	2.2	305
164	Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. <i>Blood</i> , 2012 , 120, 2826-35	2.2	293
163	Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3650-8 ²	2.2	279
162	Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3360-8	2.2	247
161	Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. <i>Blood</i> , 2011 , 117, 4726-35	2.2	247
160	FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. <i>Blood</i> , 2007 , 110, 1262-70	2.2	239
159	Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2674-81	2.2	217

158	Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4123-31	2.2	216
157	Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2739-47	2.2	216
156	The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. <i>Blood</i> , 2011 , 118, 409-12	2.2	200
155	No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. <i>Blood</i> , 2005 , 106, 3658-65	2.2	196
154	Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. <i>Blood</i> , 2005 , 106, 3768-76	2.2	180
153	A randomized comparison of daunorubicin 90 mg/m ² vs 60 mg/m ² in AML induction: results from the UK NCRI AML17 trial in 1206 patients. <i>Blood</i> , 2015 , 125, 3878-85	2.2	176
152	Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 586-95	2.2	174
151	Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5429-35	2.2	167
150	Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1293-301	2.2	148
149	European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2389-95	2.2	138
148	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	4.0	137
147	Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. <i>Blood</i> , 2013 , 122, 3322-30	2.2	134
146	International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1919-26	2.2	126
145	The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. <i>British Journal of Haematology</i> , 2009 , 145, 318-32	4.5	122
144	Independent prognostic factors for AML outcome. <i>Hematology American Society of Hematology Education Program</i> , 2009 , 385-95	3.1	120
143	Continuous versus interrupted perineal repair with standard or rapidly absorbed sutures after spontaneous vaginal birth: a randomised controlled trial. <i>Lancet, The</i> , 2002 , 359, 2217-23	4.0	112
142	Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. <i>Blood</i> , 2013 , 122, 1384-94	2.2	109
141	Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	108

140	The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. <i>Blood</i> , 2010 , 116, 2779-82	2.2	105
139	Disease evolution and outcomes in familial AML with germline CEBPA mutations. <i>Blood</i> , 2015 , 126, 1214-23	2.2	104
138	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , 2015 , 14, 1171-81	24.1	101
137	A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. <i>Blood</i> , 2017 , 129, 1143-1154	2.2	99
136	Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1486-1497	2.2	94
135	The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. <i>Blood</i> , 2010 , 115, 948-56	2.2	90
134	Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. <i>Blood</i> , 2014 , 124, 273-6	2.2	87
133	Laparoscopic uterosacral nerve ablation for alleviating chronic pelvic pain: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 955-61	27.4	84
132	Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. <i>British Journal of Haematology</i> , 2006 , 132, 576-83	4.5	81
131	Independent prognostic variables in acute myeloid leukaemia. <i>Blood Reviews</i> , 2011 , 25, 39-51	11.1	80
130	Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. <i>Blood</i> , 2013 , 121, 2424-31	2.2	75
129	Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. <i>British Journal of Haematology</i> , 2014 , 167, 214-23	4.5	67
128	Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. <i>Blood</i> , 2011 , 118, 2389-94	2.2	61
127	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. <i>Blood</i> , 2019 , 133, 1140-1151	2.2	61
126	Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2072-83	2.2	59
125	Structural and functional analysis of the human POT1-TPP1 telomeric complex. <i>Nature Communications</i> , 2017 , 8, 14928	17.4	58
124	Molecular MRD status and outcome after transplantation in NPM1-mutated AML. <i>Blood</i> , 2020 , 135, 680-688	2.2	58
123	Does BCR/ABL1 positive acute myeloid leukaemia exist?. <i>British Journal of Haematology</i> , 2013 , 161, 541-50	2.2	55

122	CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. <i>Leukemia Research</i> , 2011 , 35, 750-6	2.7	53
121	An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. <i>Haematologica</i> , 2016 , 101, 1351-1358	6.6	51
120	Continuous versus interrupted sutures for repair of episiotomy or second degree tears. <i>Cochrane Database of Systematic Reviews</i> , 2007 , CD000947		50
119	The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. <i>British Journal of Haematology</i> , 2012 , 158, 519-22	4.5	48
118	Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m ² with 6 mg/m ² in the NCRI AML17 Trial. <i>Haematologica</i> , 2016 , 101, 724-31	6.6	46
117	Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 763-9	2.2	45
116	The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.. <i>Blood</i> , 2006 , 108, 13-13	2.2	45
115	The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatment. <i>Gut</i> , 2014 , 63, 515-24	19.2	44
114	Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. <i>Blood</i> , 2015 , 125, 2923-32	2.2	43
113	Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. <i>Blood</i> , 2015 , 125, 2985-94	2.2	39
112	GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. <i>British Journal of Haematology</i> , 2013 , 161, 701-5	4.5	39
111	Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. <i>Blood</i> , 2016 , 128, 449-52	2.2	39
110	Defining the prognosis of early stage chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012 , 156, 499-507	4.5	38
109	The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. <i>Haematologica</i> , 2014 , 99, 858-64	6.6	35
108	Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013 , 160, 188-98	4.5	35
107	A randomised-controlled trial in England of a postnatal midwifery intervention on breast-feeding duration. <i>Midwifery</i> , 2006 , 22, 262-73	2.8	35
106	Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. <i>Blood</i> , 2018 , 132, 1452-1454	2.2	31
105	Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. <i>Blood</i> , 2008 , 112, 444-5; author reply 445	2.2	29

104	No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. <i>Blood</i> , 2018 , 131, 468-471	2.2	29
103	PERineal Assessment and Repair Longitudinal Study (PEARLS): protocol for a matched pair cluster trial. <i>BMC Pregnancy and Childbirth</i> , 2010 , 10, 10	3.2	25
102	Assessment of Minimal Residual Disease in Standard-Risk AML. <i>New England Journal of Medicine</i> , 2016 , 375, e9	59.2	24
101	High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018 , 8, 68	7	23
100	Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?. <i>Best Practice and Research in Clinical Haematology</i> , 2014 , 27, 53-61	4.2	23
99	A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. <i>Blood</i> , 2012 , 119, 196-205	2.2	23
98	Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice. <i>Blood</i> , 2018 , 131, 636-648	2.2	23
97	Telomere length is a critical determinant for survival in multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 94-98	4.5	21
96	KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. <i>Blood</i> , 2016 , 128, 2819-2823	2.2	19
95	AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial. <i>Blood</i> , 2013 , 122, 622-622	2.2	18
94	Telomere length is an independent prognostic marker in MDS but not in de novo AML. <i>British Journal of Haematology</i> , 2017 , 178, 240-249	4.5	16
93	Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.. <i>Blood</i> , 2007 , 110, 589-589	2.2	15
92	Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. <i>Haematologica</i> , 2016 , 101, e284-6	6.6	15
91	Long-term results of the MRC AML10 trial. <i>Clinical Advances in Hematology and Oncology</i> , 2006 , 4, 445-516	6.6	15
90	Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction. <i>Journal of Evidence-Based Medicine</i> , 2009 , 2, 196-204	6.1	14
89	A Phase II Study (BioV-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable.. <i>Blood</i> , 2006 , 108, 425-425	2.2	14
88	The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016 , 172, 573-80	4.5	14
87	Increased frequency of CD4 PD-1 HLA-DR T cells is associated with disease progression in CLL. <i>British Journal of Haematology</i> , 2020 , 188, 872-880	4.5	13

86	Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	12
85	ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1326-31 ¹⁻⁹	11.9	12
84	CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. <i>Blood Advances</i> , 2018 , 2, 964-968	7.8	12
83	Telomere length predicts for outcome to FCR chemotherapy in CLL. <i>Leukemia</i> , 2019 , 33, 1953-1963	10.7	10
82	An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts. <i>British Journal of Haematology</i> , 2015 , 170, 80-4	4.5	10
81	A Sensitive Risk Score for Directing Treatment in Younger Patients with AML.. <i>Blood</i> , 2006 , 108, 18-18	2.2	9
80	Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?. <i>British Journal of Haematology</i> , 2020 , 188, 86-100	4.5	9
79	Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020 , 188, 852-859	4.5	9
78	Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. <i>Haematologica</i> , 2018 , 103, 1654-1661 ^{6.6}	6.6	8
77	Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial.. <i>Blood</i> , 2009 , 114, 484-484	2.2	8
76	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. <i>Blood</i> , 2013 , 122, 356-356	2.2	8
75	Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data). <i>Blood</i> , 2015 , 126, 2557-2557	2.2	8
74	The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. <i>Oncotarget</i> , 2016 , 7, 16650-62	3.3	8
73	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <i>Haematologica</i> , 2020 , 105, 161-169 ^{6.6}	6.6	8
72	Measurement of beliefs about effectiveness of laparoscopic uterosacral nerve ablation. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2005 , 112, 243-6	3.7	7
71	The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial. <i>Blood</i> , 2011 , 118, 582-582	2.2	7
70	Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials. <i>Blood</i> , 2013 , 122, 358-358	2.2	7
69	HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML. <i>Blood</i> , 2015 , 126, 1307-1307	2.2	7

68	Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016 , 11, e0163291	3.7	7
67	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. <i>Journal of Clinical Oncology</i> , 2021 , 39, 890-901	2.2	7
66	Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 493-496	1.9	5
65	Variable outcome and methylation status according to mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment. <i>Haematologica</i> , 2018 , 103, 91-100	6.6	5
64	Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy. <i>British Journal of Haematology</i> , 2013 , 160, 861-3	4.5	5
63	Assessing new interventions in women's health. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2006 , 20, 713-28	4.6	5
62	A Phase Ib Study Combining the mTOR Inhibitor Everolimus (RAD001) with Low-Dose Cytarabine In Untreated Elderly AML. <i>Blood</i> , 2010 , 116, 3299-3299	2.2	5
61	Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults. <i>British Journal of Haematology</i> , 2019 , 186, 130-133	4.5	5
60	Who is an "older" patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials. <i>British Journal of Haematology</i> , 2014 , 165, 147-51	4.5	4
59	The contribution of randomized trials to the cure of haematological disorders from Bradford Hill onwards. <i>British Journal of Haematology</i> , 2012 , 158, 691-9	4.5	4
58	The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective. A Pilot Study.. <i>Blood</i> , 2006 , 108, 1950-1950	2.2	4
57	The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 Pick a Winner Comparison. <i>Blood</i> , 2010 , 116, 18-18	2.2	4
56	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. <i>British Journal of Haematology</i> , 2021 , 192, 832-842	4.5	4
55	Non-inferiority trials: No better? No worse? No change? No pain?. <i>British Journal of Haematology</i> , 2017 , 176, 883-887	4.5	3
54	Who should be transplanted in first remission of acute myeloid leukaemia?. <i>Current Treatment Options in Oncology</i> , 2011 , 12, 329-40	5.4	3
53	Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.. <i>Blood</i> , 2005 , 106, 674-674	2.2	3
52	Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 Pick a Winner Comparison. <i>Blood</i> , 2008 , 112, 2962-2962	2.2	3
51	The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial. <i>Blood</i> , 2008 , 112, 554-554	2.2	3

50	The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial. <i>Blood</i> , 2013 , 122, 493-493	2.2	3
49	Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 70-70	2.2	3
48	Axl/ Mer Inhibitor ONO-9330547 As a Novel Therapeutic Agent in a Stromal Co-Culture Model of Primary Acute Myeloid Leukaemia (AML). <i>Blood</i> , 2016 , 128, 2754-2754	2.2	3
47	The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020 , 189, e81-e86	4.5	2
46	Problems with up-front randomization in clinical trials. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5471-2; author reply 5472-3	2.2	2
45	Comparison of Cure Rates between Gemtuzumab Ozogamicin Plus Standard of Care Chemotherapy Vs Standard of Care Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2018 , 132, 2712-2712	2.2	2
44	Outcomes in Relapsed/Refractory Patients with FLT3-ITD Mutated AML Are Poor When Treated with Non-Targeted Therapy with a Potential Role for Stem Cell Transplantation: Results from the NCRI AML Trials. <i>Blood</i> , 2018 , 132, 1392-1392	2.2	2
43	Effectiveness of Clofarabine in Elderly AML Patients with Adverse Cytogenetics Unfit for Intensive Chemotherapy.. <i>Blood</i> , 2006 , 108, 1985-1985	2.2	2
42	Predictive Value of Minimal Residual Disease (MRD) Monitoring by RQ-PCR in WT1 Positive Patients Entered in the UK MRC AML-15 Trial. <i>Blood</i> , 2008 , 112, 697-697	2.2	2
41	A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2 and 6mg/m2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial. <i>Blood</i> , 2014 , 124, 2308-2308	2.2	2
40	Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future. <i>British Journal of Haematology</i> , 2020 , 188, 29-35	4.5	2
39	Will Rogers: actor, humourist and ALL epidemiologist?. <i>British Journal of Haematology</i> , 2018 , 182, 755	4.5	2
38	Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020 , 191, 231-242	4.5	1
37	Designing clinical trials in women's health. <i>Reviews in Gynaecological and Perinatal Practice</i> , 2006 , 6, 33-39		1
36	Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status. <i>Blood</i> , 2018 , 132, 2739-2739	2.2	1
35	The Achievement of Complete Remission Is Associated with Improved Quality of Life in Non-Intensively Treated Patients with Acute Myeloid Leukemia: Results of the UK NCRI LI-1 Trial. <i>Blood</i> , 2018 , 132, 372-372	2.2	1
34	A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial. <i>Blood</i> , 2008 , 112, 2960-2960	2.2	1
33	Outcome of Reduced Intensity Allografts in Patients Aged Over 45 Years with Acute Myeloid Leukaemia: Initial Results of the MRC AML15 Trial.. <i>Blood</i> , 2009 , 114, 523-523	2.2	1

32	Younger Adult Acute Myeloid Leukemia (AML) Patients with IDH2-R140 Mutations Have a Significantly Better Prognosis Than Those with Either IDH2-R172 or IDH1 Mutations. <i>Blood</i> , 2010 , 116, 100-100	2.2	1
31	Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia. <i>Blood</i> , 2011 , 118, 638-638	2.2	1
30	A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial. <i>Blood</i> , 2015 , 126, 221-221	2.2	1
29	The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy. <i>Blood</i> , 2008 , 112, 2978-2978	2.2	1
28	CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.. <i>Blood</i> , 2008 , 112, 3364-3364	2.2	1
27	A Polymorphism In the 3'UTR Region of ABCB1 Is Associated with Increased Allele Activity with Corresponding Increases In P-Glycoprotein Expression and Function. <i>Blood</i> , 2010 , 116, 3990-3990	2.2	1
26	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2013 , 122, 64-64	2.2	1
25	A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. <i>British Journal of Haematology</i> , 2021 , 194, 298-308	4.5	1
24	Cord Blood-Derived Quiescent CD34+ Cells Are More Transcriptionally Matched to AML Blasts Than Cytokine-Induced Normal Human Hematopoietic CD34+ Cells. <i>Gene Expression</i> , 2015 , 16, 169-175	3.4	
23	Research in cancer80-95		
22	Reply to D. Przepiorka et al and M.K. Jensen. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1700-1; discussion 1701	2.2	
21	Reply to S. Nagai et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e63-e64	2.2	
20	Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials. <i>British Journal of Haematology</i> , 2021 ,	4.5	
19	Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?. <i>British Journal of Haematology</i> , 2021 ,	4.5	
18	Mutation of the WilmsTumor 1 Gene Is a Poor Prognostic Factor Associated with Chemoresistance in Normal Karyotype Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 361-361	2.2	
17	Minimal Residual Disease Monitoring by RQ-PCR in Core Binding Factor Positive AML Allows Risk-Stratification and Predicts Relapse: Results of the UK MRC AML-15 Trial.. <i>Blood</i> , 2007 , 110, 543-543	2.2	
16	Telomere Length Predicts for Outcome to FCR Chemoimmunotherapy in CLL. <i>Blood</i> , 2018 , 132, 1854-1854	2.2	
15	A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia. <i>Blood</i> , 2014 , 124, 3747-3747	2.2	

14	PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia. <i>Blood</i> , 2015 , 126, 1396-1396	2.2
13	Mitochondrial profiling as a predictive biomarker for response to cytarabine-based treatment of acute myelogenous leukemia.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7017-7017	2.2
12	MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 154-154	2.2
11	Prognostic Significance of Cryptic Genomic Aberrations In AML with Normal Karyotype. <i>Blood</i> , 2010 , 116, 2729-2729	2.2
10	Detection of Immunophenotypic Residual Disease After Induction Therapy Is An Independent Prognostic Factor for Duration of Remission In Older AML Patients Treated Intensively. <i>Blood</i> , 2010 , 116, 2714-2714	2.2
9	A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls. <i>Blood</i> , 2010 , 116, 1697-1697	2.2
8	A Functional Polymorphism In the CD95 Cell Death Receptor Associated with Prognosis In Acute Promyelocytic Leukemia. <i>Blood</i> , 2010 , 116, 756-756	2.2
7	Analysis of the Interaction of Induction Regimens with P-Glycoprotein Expression In Patients with Acute Myeloid Leukaemia: Results From the MRC AML15 Trial. <i>Blood</i> , 2010 , 116, 2724-2724	2.2
6	Single Nucleotide Polymorphism Array (SNP-A) Karyotype Is the Best Predictor of Prognosis In Normal Cytogenetics Acute Myeloid Leukaemia (AML). <i>Blood</i> , 2011 , 118, 411-411	2.2
5	Mutations in a Large Cohort of Young Adult Patients with Core Binding Factor Acute Myeloid Leukemia: Impact on Outcome and the Selection of Patients for Alternative Treatment Including Transplantation in First Complete Remission. <i>Blood</i> , 2011 , 118, 419-419	2.2
4	Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of Acute Myeloid Leukemia, Not Otherwise Specified In the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2012 , 120, 540-540	2.2
3	Reduced Intensity Transplant May Improve Survival in Patients Over the Age of 40, Especially If a Sibling Donor Is Used: Pooled Analysis of 2454 Patients and 407 Transplants in the UK NCRI AML15 and AML16 Trials. <i>Blood</i> , 2012 , 120, 231-231	2.2
2	Diagnosing Diamond-Blackfan anaemia: 'Vorsprung durch Technik'. <i>British Journal of Haematology</i> , 2021 , 193, 1030-1031	4.5
1	Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia. <i>Leukemia Research</i> , 2021 , 108, 106553	2.7